Vascular Endothelial Growth Factor A (VEGFA) Antibody

Product specifications

Primary Antibodies

Target: Vascular Endothelial Growth Factor A (VEGFA)
Immunogen: abx655448 - Recombinant Vascular Endothelial Growth Factor A (VEGFA)

Mouse

Rat

WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC (Predicted): 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user.

Monoclonal

Unconjugated

IgG2b Kappa

Purified by Protein A and Protein G affinity chromatography.

100 µl

200 µl

1 ml

Liquid

WB, IHC

0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol.

Shipped within 5-7 working days.

Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.

No

L-VEGF,MVCD1,VEGF,VPF,Vascular permeability factor

Antibody anti-VEGFA

RUO

THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Descripción

VEGFA is a key member of the vascular endothelial growth factor (VEGF) family and plays a crucial role in angiogenesis, vascular permeability, and endothelial cell proliferation VEGFA binds primarily to its receptors VEGFR-1 and VEGFR-2, triggering signaling pathways like PI3K/AKT and ERK/MAPK to promote blood vessel formation during embryonic development, wound healing, and tissue repair Dysregulated VEGFA expression is associated with pathological angiogenesis observed in cancer, diabetic retinopathy, and age-related macular degeneration (AMD) VEGFA also increases vascular permeability by altering endothelial junctions, contributing to fluid leakage in conditions such as inflammation and tumors Targeted therapies, such as bevacizumab and other anti-VEGF agents, inhibit VEGFA activity to suppress angiogenesis and tumor growth in various cancers and ocular diseases

Related Products

Rat Vascular Endothelial Growth Factor A (VEGFA) Protein

Rat Vascular Endothelial Growth Factor A (VEGFA) Protein is a recombinant Rat protein expressed in E. coli.

Ver Producto